Peak Bio Inc 's Cash & cash equivalent grew by 265.67 % in the Q3 2024 sequentially, while Current Liabilities decreased, this led to improvement in Peak Bio Inc 's Quick Ratio to 0.04, Quick Ratio remained below Peak Bio Inc average.

Within Biotechnology & Pharmaceuticals industry 157 other companies have achieved higher Quick Ratio than Peak Bio Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 4029 to 4222.

Explain Quick Ratio?
How much Cash & cash equivalents PKBO�s has?
What are PKBO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PKBO Quick Ratio	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3
Y / Y Current Liabilities Change	19.72 %	33.38 %	32.42 %	90.01 %	796.18 %
Y / Y Cash & cash equivalent Change	812.95 %	9.99 %	-87.84 %	-41.72 %	24.3 %
Quick Ratio MRQ	0.04	0.01	0	0.02	0.01
PKBO's Total Ranking	# 4222	# 4029	# 4202	# 4071	# 2578
Seq. Current Liabilities Change	-6.77 %	7.85 %	8.55 %	9.7 %	3.86 %
Seq. Cash & cash equivalent Change	265.67 %	243.63 %	-82.02 %	304.14 %	-55.95 %

Quick Ratio third quarter 2024 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 158
Healthcare Sector	# 945
Overall Market	# 4222

Quick Ratio Statistics
High	Average	Low
8.52	1.11	0
(Jun 30 2021)		(Mar 31 2024)

Financial Statements
Peak Bio Inc 's Current Liabilities	$ 22 Millions	Visit PKBO's Balance sheet
Peak Bio Inc 's Cash & cash equivalent	$ 1 Millions	Visit PKBO's Balance sheet
Source of PKBO's Sales		Visit PKBO's Sales by Geography

Cumulative Peak Bio Inc 's Quick Ratio

PKBO's Quick Ratio for the trailling 12 Months

PKBO Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	38.66 %	79.22 %	154.91 %	390.09 %	1088.39 %
Y / Y Cash & cash equivalent TTM Growth	1.33 %	-48.29 %	-43.34 %	27.44 %	131.92 %
Quick Ratio TTM	0.02	0.01	0.01	0.02	0.02
Total Ranking TTM	# 3685	# 3863	# 3933	# 4524	# 3963
Seq. Current Liabilities TTM Growth	4.31 %	7.56 %	7.36 %	15.11 %	34.83 %
Seq. Cash & cash equivalent TTM Growth	98.36 %	2.82 %	-39.5 %	-17.88 %	1.22 %

Quick ratio ranking by company, industry and sector >> Back to PKBO Financial Strength Comparisons >> Go to Compare PKBO Quick Ratio to its Competitors

On the trailing twelve months basis PKBO Cash & cash equivalent more than doubled by 812.95 % in Q3 2024 year on year, faster than Current Liabilities, this led to increase in in Peak Bio Inc 's Quick Ratio to 0.02, Quick Ratio remained below PKBO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 159 other companies have achieved higher Quick Ratio than Peak Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3510 to 4185.

Explain Quick Ratio?
How much Cash & cash equivalents PKBO�s has?
What are PKBO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 160
Healthcare Sector	# 1003
Within the Market	# 4222

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.21	0.17	0.01
(Mar 31 2022)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2024 MRQ Cash & cash equivalent	Sep 30 2024 MRQ Current Liabilities
Redwoods Acquisition Corp	0.05	$ 0.051 Millions	$ 0.982 Millions
Alvotech	0.05	$ 51.428 Millions	$ 1,035.882 Millions
Cyclo Therapeutics Inc	0.05	$ 0.928 Millions	$ 18.700 Millions
Exozymes Inc	0.04	$ 0.234 Millions	$ 5.802 Millions
Peak Bio Inc	0.04	$ 0.862 Millions	$ 22.398 Millions
Ladrx Corporation	0.03	$ 0.057 Millions	$ 1.829 Millions
Brainstorm Cell Therapeutics inc	0.02	$ 0.168 Millions	$ 7.082 Millions
Zivo Bioscience Inc	0.01	$ 0.037 Millions	$ 2.579 Millions
Pelthos Therapeutics Inc	0.01	$ 0.040 Millions	$ 3.567 Millions

Date modified: 2026-09-08T15:11:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.